血清CA15-3、CEA在乳腺癌早期诊断的应用价值

The value of serum CA15-3 and CEA in the early diagnosis of breast cancer

目的通过对乳腺癌患者血清中CA15-3、CEA检测,探讨血清CA15-3、CEA对乳腺癌早期诊断的价值。方法采用化学发光微粒子免疫检测方法测定初次就诊的乳腺癌患者(128例),乳房良性疾病患者(30例)和正常对照人群(40例)的血清CA15-3、CEA。结果乳腺癌患者血清CA15-3水平高于对照组,且有统计学上意义(P<0.05),与乳房良性疾病血清CA15-3水平比较,无统计学意义(P>0.05),三组间CEA水平相比较都无统计学意义(P>0.05)。结论 血清CA15-3、CEA水平不能作为乳腺癌早期诊断指标,但CA15-3可以作为乳腺癌疾病疗效观察和预后估计。

Objective To investigate the value of the CA15-3,CEA in the early diagnosis of breast cancer.Methods 128 breast cancer patients on their initial visits,40 patients with benign breast diseases,and 30 normal controls without any tumors were included.The serum levels of CA15-3,CEA were tested by chemiluminesent microparticle immunoassay.Results The serum CA15-3 levels were higher in breast cancer patients than those in the normal controls（P〈0.05）.The serum CA15-3 levels were not significantly different in breast cancer patients and in patients with benign breast diseases（P〉0.05）.The CEA levels were not significantly different among all the three groups（P〉0.05）.Conclusions Serum CA15-3 and CEA levels can not be used in the early diagnosis of breast cancer,but CA15-3 may be indicators for evaluating the therapeutic effect and prognosis of breast cancer.